• Je něco špatně v tomto záznamu ?

Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy

T. Robak, M. Doubek, E. Ferrant, J. Diels, L. Andersone, S. Wilbertz, NC. Healy, L. Neumayr, S. van Sanden

. 2024 ; 40 (8) : 1369-1378. [pub] 20240701

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019522

OBJECTIVE: To evaluate the overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) receiving either ibrutinib monotherapy as a first-line (1L) treatment or chemotherapy/chemoimmunotherapy-based (CT/CIT) regimens in 1L followed by ibrutinib in the second line (1L CT/CIT-2L ibrutinib) after disease progression by emulating a randomized trial comparing both treatment sequences. METHODS: Patient-level data from the RESONATE-2 trial (NCT01722487) and real-world PHEDRA databases were analyzed. Three scenarios were considered using the following data sources: (1) RESONATE-2, (2) combined RESONATE-2/PHEDRA, (3) combined RESONATE-2/PHEDRA for 1L ibrutinib and PHEDRA for 1L CT/CIT-2L ibrutinib. Propensity score-based weights and inverse probability of censoring weighting were used to adjust for baseline (Scenarios 2 and 3) and time-dependent confounding (all scenarios), and to address potential biases. A weighted Cox proportional hazards model was used to estimate the OS hazard ratio (HR) and 95% confidence interval (CI) for 1L ibrutinib versus 1L CT/CIT-2L ibrutinib. RESULTS: Results from Scenario 1 showed a significantly lower risk of death with 1L ibrutinib compared with 1L chlorambucil followed by 2L ibrutinib (HR 0.35 [95% CI 0.20-0.62]). Results from Scenarios 2 and 3 demonstrated a reduced risk of death with 1L ibrutinib compared with 1L CT/CIT-2L ibrutinib (HR 0.35 [0.21-0.61] and 0.64 [0.39-1.04], respectively). CONCLUSION: The analyses consistently showed a reduced risk of death when ibrutinib was used as a 1L treatment in CLL compared with delaying its use until 2L after CT/CIT regimens, which suggests that initiating ibrutinib in 1L is advantageous for improving survival outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019522
003      
CZ-PrNML
005      
20241024110756.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/03007995.2024.2368175 $2 doi
035    __
$a (PubMed)38885086
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Robak, Tadeusz $u Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
245    10
$a Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy / $c T. Robak, M. Doubek, E. Ferrant, J. Diels, L. Andersone, S. Wilbertz, NC. Healy, L. Neumayr, S. van Sanden
520    9_
$a OBJECTIVE: To evaluate the overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) receiving either ibrutinib monotherapy as a first-line (1L) treatment or chemotherapy/chemoimmunotherapy-based (CT/CIT) regimens in 1L followed by ibrutinib in the second line (1L CT/CIT-2L ibrutinib) after disease progression by emulating a randomized trial comparing both treatment sequences. METHODS: Patient-level data from the RESONATE-2 trial (NCT01722487) and real-world PHEDRA databases were analyzed. Three scenarios were considered using the following data sources: (1) RESONATE-2, (2) combined RESONATE-2/PHEDRA, (3) combined RESONATE-2/PHEDRA for 1L ibrutinib and PHEDRA for 1L CT/CIT-2L ibrutinib. Propensity score-based weights and inverse probability of censoring weighting were used to adjust for baseline (Scenarios 2 and 3) and time-dependent confounding (all scenarios), and to address potential biases. A weighted Cox proportional hazards model was used to estimate the OS hazard ratio (HR) and 95% confidence interval (CI) for 1L ibrutinib versus 1L CT/CIT-2L ibrutinib. RESULTS: Results from Scenario 1 showed a significantly lower risk of death with 1L ibrutinib compared with 1L chlorambucil followed by 2L ibrutinib (HR 0.35 [95% CI 0.20-0.62]). Results from Scenarios 2 and 3 demonstrated a reduced risk of death with 1L ibrutinib compared with 1L CT/CIT-2L ibrutinib (HR 0.35 [0.21-0.61] and 0.64 [0.39-1.04], respectively). CONCLUSION: The analyses consistently showed a reduced risk of death when ibrutinib was used as a 1L treatment in CLL compared with delaying its use until 2L after CT/CIT regimens, which suggests that initiating ibrutinib in 1L is advantageous for improving survival outcomes.
650    _2
$a lidé $7 D006801
650    12
$a adenin $x analogy a deriváty $x terapeutické užití $7 D000225
650    12
$a chronická lymfatická leukemie $x farmakoterapie $x mortalita $7 D015451
650    12
$a piperidiny $x terapeutické užití $x aplikace a dávkování $7 D010880
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a pyrimidiny $x terapeutické užití $x aplikace a dávkování $7 D011743
650    12
$a pyrazoly $x terapeutické užití $x aplikace a dávkování $7 D011720
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x aplikace a dávkování $7 D000971
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Doubek, Michael $u Internal Medicine - Hematology and Oncology Department, University Hospital Brno, Brno, Czech Republic
700    1_
$a Ferrant, Emmanuelle $u Department of Hematology, Hôpital Lyon-Sud, Lyon, France
700    1_
$a Diels, Joris $u Janssen Pharmaceutica NV, Beerse, Belgium
700    1_
$a Andersone, Liva $u UAB "JOHNSON & JOHNSON" filiale Latvija, Riga, Latvia
700    1_
$a Wilbertz, Sabine $u Janssen-Cilag GmbH, Neuss, Germany
700    1_
$a Healy, Nollaig C $u Janssen Sciences Ireland UC, Cork, Ireland
700    1_
$a Neumayr, Lynne $u Pharmacyclics, an AbbVie Company, Sunnyvale, California, USA
700    1_
$a van Sanden, Suzy $u Janssen Pharmaceutica NV, Beerse, Belgium
773    0_
$w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 40, č. 8 (2024), s. 1369-1378
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38885086 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110750 $b ABA008
999    __
$a ok $b bmc $g 2202009 $s 1231495
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 40 $c 8 $d 1369-1378 $e 20240701 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace